Details for Patent: 10,570,139
✉ Email this page to a colleague
Which drugs does patent 10,570,139 protect, and when does it expire?
Patent 10,570,139 protects BRUKINSA and is included in one NDA.
This patent has thirty-four patent family members in twenty-seven countries.
Summary for Patent: 10,570,139
Title: | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Abstract: | The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001## |
Inventor(s): | Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN) |
Assignee: | BEIGENE SWITZERLAND GMBH (Basel, CH) |
Application Number: | 15/969,864 |
Patent Claim Types: see list of patent claims | Use; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 10,570,139
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA | ⤷ Try for Free | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Try for Free | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) | ⤷ Try for Free | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY | ⤷ Try for Free | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,570,139
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
PCT/CN2013/074728 | Apr 25, 2013 |
International Family Members for US Patent 10,570,139
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2989106 | ⤷ Try for Free | 301161 | Netherlands | ⤷ Try for Free |
European Patent Office | 2989106 | ⤷ Try for Free | PA2022504 | Lithuania | ⤷ Try for Free |
European Patent Office | 2989106 | ⤷ Try for Free | LUC00250 | Luxembourg | ⤷ Try for Free |
European Patent Office | 2989106 | ⤷ Try for Free | CA 2022 00008 | Denmark | ⤷ Try for Free |
European Patent Office | 2989106 | ⤷ Try for Free | 122022000013 | Germany | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |